Open AccessThe potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection
Author(s) -
Dimitra Ioanna Lampropoulou,
Vanessa-Meletia Bala,
Eleni Zerva,
Evangelia Pliakou,
Dimitrios Filippou,
Maria Gazouli,
Gerasimos Aravantinos
Publication year - 2022
Publication title -
journal of infection in developing countries
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.322
H-Index - 49
eISSN - 2036-6590
pISSN - 1972-2680
DOI - 10.3855/jidc.15386
Subject(s) - bevacizumab , vascular endothelial growth factor , covid-19 , medicine , pandemic , coronavirus , vascular endothelial growth factor a , angiogenesis , immunology , virology , pharmacology , infectious disease (medical specialty) , cancer research , disease , vegf receptors , chemotherapy
During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.
Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.
Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.